JP2006505621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006505621A5 JP2006505621A5 JP2005501247A JP2005501247A JP2006505621A5 JP 2006505621 A5 JP2006505621 A5 JP 2006505621A5 JP 2005501247 A JP2005501247 A JP 2005501247A JP 2005501247 A JP2005501247 A JP 2005501247A JP 2006505621 A5 JP2006505621 A5 JP 2006505621A5
- Authority
- JP
- Japan
- Prior art keywords
- side chain
- composition according
- compound
- inflammatory bowel
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 206010056979 Colitis microscopic Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 2
- 229930182832 D-phenylalanine Natural products 0.000 claims 2
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 claims 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 208000010227 enterocolitis Diseases 0.000 claims 2
- 208000004341 lymphocytic colitis Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229960005190 phenylalanine Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229960004799 tryptophan Drugs 0.000 claims 2
- UJOQOPBFLFQOJJ-HXUWFJFHSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-methylhexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UJOQOPBFLFQOJJ-HXUWFJFHSA-N 0.000 claims 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims 1
- YOKBGCTZYPOSQM-HPSWDUTRSA-N (2s)-2-acetamido-n-[(3s,9s,12s,15r,18s)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1h-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide Chemical compound C([C@H](NC(=O)C)C(=O)N[C@@H]1C(N2CCC[C@H]2C(=O)N[C@H](CC2CCCCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC1)=O)C1=CC=CC=C1 YOKBGCTZYPOSQM-HPSWDUTRSA-N 0.000 claims 1
- GAUUPDQWKHTCAX-VIFPVBQESA-N (2s)-2-amino-3-(1-benzothiophen-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CSC2=C1 GAUUPDQWKHTCAX-VIFPVBQESA-N 0.000 claims 1
- ADJZXDVMJPTFKT-JTQLQIEISA-N (2s)-2-azaniumyl-4-(1h-indol-3-yl)butanoate Chemical compound C1=CC=C2C(CC[C@H](N)C(O)=O)=CNC2=C1 ADJZXDVMJPTFKT-JTQLQIEISA-N 0.000 claims 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 1
- MXHKOHWUQAULOV-UHFFFAOYSA-N 2-azaniumyl-4-cyclohexylbutanoate Chemical compound OC(=O)C(N)CCC1CCCCC1 MXHKOHWUQAULOV-UHFFFAOYSA-N 0.000 claims 1
- 108010048280 AcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg) Proteins 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 229940126639 Compound 33 Drugs 0.000 claims 1
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims 1
- 229930195715 D-glutamine Natural products 0.000 claims 1
- -1 D-homo-norleucine Chemical compound 0.000 claims 1
- 229930182819 D-leucine Natural products 0.000 claims 1
- LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical compound CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 1
- 229930195709 D-tyrosine Natural products 0.000 claims 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 1
- 229930182831 D-valine Natural products 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 229940123344 GPR antagonist Drugs 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 1
- LOOZZTFGSTZNRX-VIFPVBQESA-N L-Homotyrosine Chemical compound OC(=O)[C@@H](N)CCC1=CC=C(O)C=C1 LOOZZTFGSTZNRX-VIFPVBQESA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 claims 1
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000012896 Peritoneal disease Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 208000008609 collagenous colitis Diseases 0.000 claims 1
- ORQXBVXKBGUSBA-UHFFFAOYSA-N cyclohexyl D-alanine Natural products OC(=O)C(N)CC1CCCCC1 ORQXBVXKBGUSBA-UHFFFAOYSA-N 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OFYAYGJCPXRNBL-LBPRGKRZSA-N naphthalen-2-yl-3-alanine Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-LBPRGKRZSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 206010035485 plasmacytosis Diseases 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N tetrahydro-isoquinoline Natural products C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 1
- 125000005425 toluyl group Chemical group 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004441 tyrosine Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002952084 | 2002-10-16 | ||
| AU2002952084A AU2002952084A0 (en) | 2002-10-16 | 2002-10-16 | Treatment of inflammatory bowel disease |
| AU2003902452A AU2003902452A0 (en) | 2003-05-20 | 2003-05-20 | Treatment of inflammatory bowel disease |
| AU2003902452 | 2003-05-20 | ||
| PCT/AU2003/001365 WO2004035078A1 (en) | 2002-10-16 | 2003-10-15 | Treatment of inflammatory bowel disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006505621A JP2006505621A (ja) | 2006-02-16 |
| JP2006505621A5 true JP2006505621A5 (enExample) | 2006-11-24 |
| JP4818726B2 JP4818726B2 (ja) | 2011-11-16 |
Family
ID=32108554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501247A Expired - Fee Related JP4818726B2 (ja) | 2002-10-16 | 2003-10-15 | 炎症性腸疾患の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7410945B2 (enExample) |
| EP (1) | EP1558277B1 (enExample) |
| JP (1) | JP4818726B2 (enExample) |
| AT (1) | ATE509632T1 (enExample) |
| CA (1) | CA2542507C (enExample) |
| WO (1) | WO2004035078A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
| US7410945B2 (en) * | 2002-10-16 | 2008-08-12 | The University Of Queensland | Treatment of inflammatory bowel disease |
| AU2002952086A0 (en) * | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
| US7885748B2 (en) * | 2006-09-13 | 2011-02-08 | Gm Global Technology Operations, Inc. | Virtual accelerometer |
| CA2699157A1 (en) | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2009052489A2 (en) * | 2007-10-19 | 2009-04-23 | Alba Therapeutics Corporation | Novel inhibitors of mammalian tight junction opening |
| SG157299A1 (en) * | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| KR101724161B1 (ko) * | 2008-08-27 | 2017-04-06 | 칼시메디카, 인크 | 세포내 칼슘을 조절하는 화합물 |
| US8524763B2 (en) * | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| US8618307B2 (en) | 2009-09-16 | 2013-12-31 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2019075319A1 (en) * | 2017-10-12 | 2019-04-18 | Board Of Regents, The University Of Texas System | COMPOSITIONS AND METHODS FOR TREATING PAIN IN WOMEN |
| CN116115582B (zh) * | 2022-11-10 | 2024-04-16 | 重庆大学 | 前药封装的工程化益生菌及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807824A (en) * | 1993-12-06 | 1998-09-15 | Ciba-Geigy Corporation | C5A receptor antagonists having substantially no agonist activity |
| EP0749488A1 (en) * | 1994-03-03 | 1996-12-27 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
| US5614370A (en) * | 1994-03-18 | 1997-03-25 | Merck & Co., Inc. | Assay to identify human C5a antagonists and agonists |
| JPH11507215A (ja) * | 1995-06-05 | 1999-06-29 | ノバルティス・アクチエンゲゼルシャフト | アゴニスト活性を実質的にもたないＣ５ａ受容体アンタゴニストおよび製造方法 |
| SE9701219D0 (sv) * | 1997-04-04 | 1997-04-04 | Astra Pharma Prod | New compounds |
| AUPO755097A0 (en) * | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| US6611377B1 (en) * | 2000-07-10 | 2003-08-26 | Intel Corporation | Micromechanical diffraction phase grating |
| AUPR833401A0 (en) * | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
| AUPS160602A0 (en) * | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
| US7410945B2 (en) * | 2002-10-16 | 2008-08-12 | The University Of Queensland | Treatment of inflammatory bowel disease |
| AU2002952086A0 (en) * | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
| AU2003902586A0 (en) * | 2003-05-26 | 2003-06-12 | The University Of Queensland | Treatment of burns |
| US7910945B2 (en) * | 2006-06-30 | 2011-03-22 | Cree, Inc. | Nickel tin bonding system with barrier layer for semiconductor wafers and devices |
-
2003
- 2003-10-15 US US10/531,564 patent/US7410945B2/en not_active Expired - Fee Related
- 2003-10-15 AT AT03750165T patent/ATE509632T1/de not_active IP Right Cessation
- 2003-10-15 CA CA2542507A patent/CA2542507C/en not_active Expired - Fee Related
- 2003-10-15 WO PCT/AU2003/001365 patent/WO2004035078A1/en not_active Ceased
- 2003-10-15 EP EP03750165A patent/EP1558277B1/en not_active Expired - Lifetime
- 2003-10-15 JP JP2005501247A patent/JP4818726B2/ja not_active Expired - Fee Related
-
2008
- 2008-06-23 US US12/144,266 patent/US20090004264A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006505621A5 (enExample) | ||
| HRP950276A2 (en) | New amino acid derivatives, process for their preparation and pharmaceutical compounds (ii) containing such compounds | |
| CA2463675A1 (en) | Cyclic peptides as g-protein-coupled receptor antagonists | |
| JP2019089773A (ja) | ミトコンドリア透過性転移の阻止方法 | |
| Schröder et al. | The Peptides: Methods of peptide synthesis | |
| Sagan et al. | N-and Cα-methylation in biologically active peptides: synthesis, structural and functional aspects | |
| JP2002514611A5 (enExample) | ||
| JP2008518978A5 (enExample) | ||
| JP2013508346A5 (enExample) | ||
| JP2007518818A5 (enExample) | ||
| JP2006505555A5 (enExample) | ||
| SK65094A3 (en) | Aminoacid derivatives, process for producing the same and pharmaceutical compositions containing these derivatives | |
| JP2010529957A5 (enExample) | ||
| WO2001040262A1 (en) | Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease | |
| BR112012011332B1 (pt) | Agentes direcionados para gadd45beta | |
| JP2013511554A5 (enExample) | ||
| AU2005245962A1 (en) | Bacterial efflux pump inhibitors and methods of treating bacterial infections | |
| JP2004521123A5 (enExample) | ||
| SI9420001B (sl) | Polipeptidni antagonisti bombezina | |
| JP2006528208A5 (enExample) | ||
| CN114126619B (zh) | 用于合成肽模拟物的化合物 | |
| JP2007517038A5 (enExample) | ||
| JP2006505556A5 (enExample) | ||
| EP0783521B1 (en) | Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone | |
| CN1787831A (zh) | 用于防止线粒体通透性改变的方法 |